Please share what your organisation and Boehringer Ingelheim will Co-Create together
MicroClinic Technologies is eager co-create with Boehringer Ingelheim (BI) to improve last mile diagnosis and treatment of cardiovascular disease (CVD) and stroke in five underserved regions in Kenya. ONE HUNDRED Private clinics serving densely populated peri-urban dwellings will be trained on a cardiovascular disease (CVD) screening protocol, which would be co-designed with BI and embedded in the MicroClinic’s existing ZiDi™ health management software. The screening protocol will be reinforced by a coupon/loyalty program, where clinics earn points for adhering to the CVD protocol that can then be converted into coupons for the purchase of electro cardiogram devices to better serve patients.
If you selected "other" above, please explain:
Please provide a 1-2 sentence summary of your Co-Creation idea
A cardiovascular disease screening program reinforced by a loyalty point program will strengthen and incentivize last mile early detection and treatment of CVDs, notably, in peri-urban dwellings of Kenya. This project will serve as a model to improve and scale point-of-care diagnoses and treatment of chronic diseases in resource-limited, nurse operated settings. It will spur sector-wide surveillance of CVD and enable adoption of electronic medical records in Kenya.
How does this project link to the core mission of your organisation?
MicroClinic Technologies seeks to transform healthcare at the last mile by improving access to affordable diagnostics and medicines at the Point-of-care using ZiDi™. ZiDi™ helps health workers, most of whom are nurses, to better diagnose disease. This co-creation would help MicroClinic to build out its existing ZiDi™ platform to include CVD protocols and to expand its loyalty program to track adherence. The loyalty program is a technology-powered solution that is scalable across Africa.
Beyond social impact, how does this project link to Boehringer Ingelheim’s core business?
Stroke care is a core strategic area of focus for BI. Also, Kenya is one of BI’s priority markets on the African continent. This proposal touches on both; this co-creation would provide BI with an opportunity to play a role in building out stroke care (education, detection and treatment) in communities where there is a large unmet need in Africa.
What are the specific inputs and actions that each side will contribute to this Co-Creation idea based on each of your unique competencies and experiences?
My organization will contribute:
MicroClinic will provide access to ZiDi™ in a target 100 clinics, thanks to a grant received from KfW-DEG (a program of GIZ) to expand access to ZiDi™ in private high-volume clinics serving peri-urban and rural regions in Kenya. We will sync the CVD screening protocols with the loyalty point system in ZiDi™.
Clinics will earn loyalty points based on adherence to the protocol. We will distribute the relevant devices like ECGs to clinics that achieve their target number of loyalty points.
Boehringer Ingelheim will contribute:
Boehringer Ingelheim will help us develop an effective and easy-to-use CVD screening protocol to facilitate early detection and treatment of stroke or other related diseases in clinics using ZiDi™ or any other health records management system. BI can help develop training videos or visual aids on the screening protocol which the health workers can access through ZiDi™ in the target facilities. BI (potentially with another partner) will donate the coupons which clinics can claim upon achieving the requisite loyalty points.
Please describe the potential revenue model for this Co-Creation idea.
We anticipate a win-win-win for the clinic, MicroClinic and BI. Clinics on ZiDi™ auto-generate claims and achieve better compliance with the multiple private insurers they work with and get reimbursed at better rates by the insurers thus improving their revenue. MicroClinic charges clinics a fee of 25-50 cents per patient, and will benefit with more uptake of ZiDi™ in clinics. The program will favour a needs-based demand for medicines to treat CVD in a chronically underserved market, which is good for BI’s social commitments and sustainable business imperatives.
What possible risks or challenges do you foresee?
TIME SPENT PER CASE: Health workers tend to resist protocols that add to the duration of the patient visit. Adding a CVD protocol would extend the duration of patient visits in an already resource constrained setting.
TRAINING: On-going technical support would be needed to enhance the skills of health workers vis-à-vis the management of ‘uncovered” chronic diseases like stroke.
APPEARANCE OF CONFLICT: Given that ZiDi™ collects patient data, this program will have to establish a firewall between patient level data and BI involvement.
Is there anything else you would like to share about your Co-Creation idea?
This idea is about achieving a much needed transformational change in health service delivery. Besides achieving sector-wide skills development of health workers and improving last mile access to care and treatment for CVDs in 100 clinics, this program will have the incremental benefit of improving quality of care for ~1 million patients per year, as well as create 100 rural health IT jobs for youth. MicroClinic Technologies will recruit, train and support 100 youth to maintain ZiDi™ and the equipment placed in the facilities. Demonstrating early impact will attract other ecosystem players into the coupon program to scale.
If you selected "other" above, please explain:
▢ I’d like to implement together
Besides Boehringer Ingelheim, what other types of partners might be valuable to carrying out your Co-Creation idea, and why?
Riders for Health – we intend to engage Riders to facilitate last mile logistics for our technical support staff. Technical staff can rent bikes from Riders to facilitate access to the facilities.
Insurance companies – low-cost diagnosis and treatment of chronic diseases could be attractive to insurances providers, like Changamka. They may offer our clinics preferential rates coupled with real-time adjudication of claims.
SAP – We are partnering with SAP to optimize the analytic capabilities of ZiDi™ to better serve the clinics.
Distributors of drugs – We will link clinics to wholesalers via our web-portal to facilitate orders for safe medicines at affordable rates.